

# Accepted Manuscript

An update on lymphocyte subtypes in Asthma and Airway Disease


Daniel M. Moldaver, BSc, Mark Larché, PhD, Christopher D. Rudulier, PhD

PII: S0012-3692(16)62326-7

DOI: [10.1016/j.chest.2016.10.038](https://doi.org/10.1016/j.chest.2016.10.038)

Reference: CHEST 783

To appear in: *CHEST*



Please cite this article as: Moldaver DM, Larché M, Rudulier CD, An update on lymphocyte subtypes in Asthma and Airway Disease, *CHEST* (2016), doi: 10.1016/j.chest.2016.10.038.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

An update on lymphocyte subtypes in Asthma and Airway Disease

**Daniel M. Moldaver<sup>1</sup>, BSc, Mark Larché<sup>1†</sup>, PhD and Christopher D. Rudulier<sup>2</sup>, PhD**

<sup>1</sup>Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Divisions of Respiriology and Clinical Immunology & Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada. <sup>2</sup>Division of Respiriology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

**Running title:** New T Cell subtypes in Airway Disease

**† Correspondence address:**

**Dr. Mark Larché**, Firestone Institute for Respiratory Health, Divisions of Clinical Immunology & Allergy and Respiriology, Department of Medicine, McMaster University, T2131-1, 2nd Floor, Juravinski Tower, St. Joseph's Hospital Healthcare, 50 Charlton Avenue East, Hamilton, ON, L8N 4A6

e-mail: [larche@mcmaster.ca](mailto:larche@mcmaster.ca)

## Disclosure

M. Larché is a co-founder, and consultant of Circassia Ltd., a stockholder of Circassia Pharmaceuticals PLC, a founding scientist and consultant of Adiga Life Sciences Inc. and has received research support from both of these companies. ML consulted for UCB and Aravax Pty in the 12 months prior to publication of this article. DM and CD declare no conflict of interest

## Abstract

Download English Version:

<https://daneshyari.com/en/article/5600934>

Download Persian Version:

<https://daneshyari.com/article/5600934>

[Daneshyari.com](https://daneshyari.com)